ACTIVELLA Drug Patent Profile

When do Activella patents expire, and what generic alternatives are available?

Activella is a drug marketed by Amneal and is included in one NDA.

The generic ingredient in ACTIVELLA is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Activella

A generic version of ACTIVELLA was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17^th, 2008.

Summary for ACTIVELLA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACTIVELLA

US Patents and Regulatory Information for ACTIVELLA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907-002	Dec 28, 2006		DISCN	Yes	No
Amneal	ACTIVELLA	estradiol; norethindrone acetate	TABLET;ORAL	020907-001	Nov 18, 1998	AB	RX	Yes	Yes

International Patents for ACTIVELLA

See the table below for patents covering ACTIVELLA around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	970037
Netherlands	300022
Denmark	377084
Luxembourg	90697

Supplementary Protection Certificates for ACTIVELLA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0136011	SPC/GB00/028	United Kingdom		SPC/GB00/028: 20040802, EXPIRES: 20090801
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
0136011	SPC/GB98/034	United Kingdom		SPC/GB98/034: 20040802, EXPIRES: 20090801

ACTIVELLA (estradiol acetate/estradiol hemihydrate + norethindrone acetate): Investment Scenario and Patent-Driven Fundamentals

Last updated: April 23, 2026

What is Activella and where does it sit in the market?

Activella is a branded menopausal hormone therapy (MHT) indicated for treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and for prevention of postmenopausal osteoporosis in women at risk. It is an oral combination product containing estradiol (estrogen) plus norethindrone acetate (progestin).

Core product composition (brand)

• Estradiol + Norethindrone acetate (oral combination)

Typical commercial positioning (industry-standard)

• Prescription MHT category with competitive pressure from generics and competing branded MHTs
• Revenue profile is driven by:
  • remaining exclusivity (if any),
  • patent estate strength (orange-book linked patents),
  • payer dynamics for branded vs generic switch.

What does the patent estate imply for future pricing and revenue?

For investment analysis, the decisive variable is whether Activella has any enforceable US patent protection that can block generic entry, and the extent of patent-life remaining.

Patent estate evaluation (US)

• Activella is widely available as generic(s) in the US, indicating that the original branded exclusivities are not currently a dominant barrier to generic competition.
• When generics have entered, branded MHT pricing typically compresses quickly and sales shift from branded to lowest-cost alternatives, unless the brand maintains a meaningful differentiation (formulation, dosing convenience, REMS-like constraints, or strong payer contracts). No such differentiation is indicated by the availability of multiple generic equivalents.

Investment implication: Activella’s forward fundamentals are likely constrained by the economics of an established, generically available oral MHT product, where incremental upside depends on:

• market-share retention in specific payer segments,
• contract positioning for brands,
• any late-cycle patent thickets (process/polymorph/formulation) that can slow generic launches.

Practical conclusion for investors

• The realistic base case for Activella is a mature, generic-exposed franchise.
• Upside cases are driven by localized holdouts (narrow formulation/process claims, settlements that extend exclusivity, or continued brand access through managed-care contracts). Those are event-driven, not structural.

What are the key fundamentals that move Activella returns?

1) Generic erosion curve and gross-to-net pressure

After generic entry in established MHTs, branded revenue typically faces:

• lower list pricing vs branded peers,
• higher rebates and discounts,
• faster share loss.

For investors, the key is the gross-to-net trend and whether it stabilizes or keeps deteriorating. With generic presence, gross margin can remain stable for a time only if net pricing does not collapse further, which is uncommon without contract protection.

2) Competitive landscape inside oral combined MHT

Activella competes within:

• other oral combined MHT brands (if any),
• generic estradiol/progestin combinations,
• and increasingly, preference shifts to different progestin strategies or alternative routes (transdermal is often used when tolerability matters).

Even when Activella’s label remains clinically acceptable, prescribers and payers often shift toward:

• lower acquisition cost generics,
• plan-preferred regimens.

3) Reimbursement dynamics and managed-care formularies

For mature MHTs, payer committees largely drive:

• tier placement (preferred vs non-preferred),
• prior authorization or step therapy,
• restrictions for older age bands or risk stratification.

Branded products survive when they secure preferred status. Generic availability weakens that leverage.

What is the investment scenario: base, bull, bear?

Base case (most likely)

• Activella remains a steady but contracting revenue stream as generic availability caps pricing power.
• Portfolio value comes from cash generation and potential episodic contract-driven stabilization.
• Downside risk increases if payer coverage tightens further or competing generics gain cost advantage.

Bull case (event-driven upside)

• Brand retains disproportionate share via:
  • favorable payer contracting,
  • slow switching in specific geographies,
  • or continued differentiation in patient adherence (less common for a generic-exposed oral product).
• Any delayed generic entry or settlement-driven runway would be additive, but the market has already demonstrated generic access.

Bear case (downside)

• Accelerated formulary placement to generic-only coverage.
• Additional margin compression through higher rebates and increased net-to-list discounts.
• Higher channel inventory pressure if demand softens with shifting prescriber behavior in MHT.

Where are the highest-value diligence checks for investors?

1) Orange Book status and the active patent inventory

Investors should focus on:

• whether any US patents associated with Activella are still enforceable and listed as contributing to exclusivity,
• patent types (composition, formulation, method of use, process) and their likely generic design-around risk,
• whether any Paragraph IV filings have produced settlement signals.

2) Hatch-Waxman settlement history (if any)

For generics, settlements often determine timing of launch and revenue impact to the brand. Any settlement history shifts the revenue forecast from “generic already launched” to “generic timing may have been delayed.” For Activella, generic availability signals the market has already moved past the likely initial launch barriers, but investors still should check for later-wave settlements tied to follow-on patents.

3) US sales trend and net price realization

• The key metric is net sales and gross-to-net.
• If net price is stabilizing despite generic pressure, the brand has contract resilience.
• If gross-to-net keeps worsening, the forecast should assume continued erosion.

How does Activella’s franchise risk profile compare to typical MHT generics?

Oral combined MHT products typically have:

• predictable generic substitution,
• label-driven prescribing but strong payer influence,
• sensitivity to safety communications, which can change overall class demand.

Activella’s risk profile is therefore aligned with generic-exposed MHT benchmarks:

• structurally limited pricing power after generic entry,
• investment returns tied to execution in managed care and cost competitiveness.

What valuation logic fits a mature, generic-exposed Activella asset?

For a branded but generics-exposed pharmaceutical:

• Value is closer to a cash-flow duration problem than a growth problem.
• Investors typically underwrite:
  • stable or slowly declining revenues,
  • controlled manufacturing costs,
  • and a realistic endgame for brand share.

Discount rates should reflect:

• rapid generic substitution risk,
• inability to fund meaningful long-cycle R&D differentiation unless the company has pipeline options tied to the franchise.

Key Takeaways

• Activella is an oral combined menopausal hormone therapy (estradiol + norethindrone acetate) in a mature category.
• Generic availability implies limited structural protection against pricing compression.
• Forward fundamentals depend on gross-to-net control, formulary access, and any late-cycle patent or settlement events that affect timing of additional generic erosion.
• Best-fit investor underwriting is cash-flow durability rather than growth, with downside driven by managed-care tiering and ongoing rebate pressure.

FAQs

1. Is Activella still protected by meaningful US patent exclusivity?
   Generic availability indicates the original branded exclusivity barrier is no longer a dominant constraint; investors should treat the product as generic-exposed.

2. What most affects Activella revenue in the US?
   Net pricing (gross-to-net) and formulary placement are usually the primary drivers.

3. What market forces drive MHT generic substitution?
   Payer cost controls, switching behavior, and availability of equivalent generic regimens.

4. Does differentiation matter for Activella after generic entry?
   It matters only if it creates payer or prescriber lock-in; otherwise economics favor lowest-cost alternatives.

5. How should investors model Activella’s endgame?
   Use a revenue decline with potential stabilization windows tied to contracts; assume incremental share loss unless offset by pricing discipline or delayed competition.

---

References

[1] DailyMed. “ACTIVELLA (estradiol and norethindrone acetate) tablets.” National Library of Medicine. https://dailymed.nlm.nih.gov/
[2] FDA. Drugs@FDA database entry for Activella. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search term: Activella). https://www.accessdata.fda.gov/scripts/cder/ob/